Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript

Good afternoon, everyone, and welcome to the Karis Life Sciences Third Quarter 2026 earnings call. My name is Lisa, and I will be your conference operator today. All participants are on a listen-only mode. After the prepared remarks, there will be a question-and-answer session. As a reminder, this call is being recorded. I would now like to hand it over to Russ Denton at Karis.

Please go ahead. Sciences released financial results for the quarter ended September 30, 2026. Joining from CARES today are David Dean Holbert, our founder, chairman, and CEO, David Spetzler, our president, Brian Rilley, our vice chairman and EVP, and Luke Power, our CFO. Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations that involve risk and uncertainties that could cause actual results to materially differ from those anticipated. For a discussion of the factors that could affect our future results, please refer to our SEC filing. We undertake no obligation to update these statements except as required by law. This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specifications. and measures, the most directly comparable gap measures, are provided in today's earnings release. A copy of today's presentation materials can be found on our Investor Relations website. I'll now turn the call over to our Founder, Chairman, and CEO, David Dean Holber. David. Thanks, everyone, for joining.

This was another record quarter for us with volume of 21% to 61,500 cases, and our revenue grew 27% to 275 million. What I like most about these numbers is that they are the continued result of a plan. At the start of the year, we realigned and expanded the sales organization and invested in the lab ahead of the demand we expected. Since then, we have delivered two consecutive quarters of acceleration, and this quarter's year-over-year volume growth is the strongest we've posted in over a year, and we expect that trend to continue into the fourth quarter. We have also taken the same approach with the product pipeline, where we have launched four products so far this year, and by year-end, we'll launch our fifth, Keras Confirm, our whole genome MRD assay. And complete our comprehensive approach across the patient journey. And comprehensive isn't just a slogan for us. And you can see that as recently as September, where we launched a new version of CareSassure for therapy selection that reads the therapy-relevant genes at 40,000 X depth and takes our RNA reads past 600 million. I always say deeper, not cheaper, as the depth and breadth of an assay is what matters, allowing us to continue to drive the science forward. I made the decision to take the company to Whole Exome, Whole Transcriptome, back in 2018, and that has produced our Exome platform, which includes MyCancerSeq, CareSassure for therapy selection, and now CareSassure for monitoring. We're taking the same approach for our next phase with expanding to whole genome, and you can see this in our approach for early stage detection, therapy selection, and MRD. Now, with regards to Keras Detect, I told you in August that the interest had run ahead of even my own expectations, and it has, but we're not going to chase it by overspending. We're building this deliberately. We launched two national campaigns with Kevin Costner and Jordan Speed. Both of whom I've had the pleasure of sitting down with to discuss their reasons for participating in our ads. And we will continue to roll out and expand these into new markets and Q4 and beyond. Also, our next campaign will be focused on educating the public regarding performance and understanding of stage. The whole idea behind early detection is to catch the cancer while it is still treatable before it spreads. Meaning early stage one and two. After that, it's likely not to be treatable. And sadly, the tests being marketed currently use a technology called methylation. And a methylation-only approach doesn't work in early stages for most cancers. And it's unclear why someone would reorder one. Like a poop test for one cancer when you could take a blood test for over 50 different cancers. That's exactly why we built Keras Detect on a whole genome. It's designed to find cancer at those early treatable stages. We'll keep building it that way, and as David will discuss in a few minutes, we are also going to continue to demonstrate our best-in-class performance by expanding our ACHIEVE program. So I feel great about where we are. We went deeper when others went cheaper. We built a plan that is working, and we're funding every bit of it ourselves while we manage the P&L. We'll keep making decisions the way we always have, by the mom rule. If it were my mom, I'd want her to get the most complete answer possible. Every patient deserves that, and that's how we'll make precision medicine a reality. Brian, over to you.

Thanks, David, and thank you all for joining our third quarter 2026 earnings call. This is another record quarter, and an extremely important quarter for Keras. First, the commercial strategy and investment is working and is delivering accelerating volume growth. In addition, the MSED launch is advancing well with important new potential channel partners who are excited about Keras2Tech's technology and specifically early-stage sensitivity. We're also announcing our entry into the MRD and monitoring market with the launch this quarter of Keras Assure Therapy Response Monitoring. This will be followed by the upcoming launch in December of Keras Confirmed for MRD. And with the launch of these products, we now have the best molecular technology across the entire cancer care continuum. And we did all of this while delivering sustained growth and profitability. Our commercial strategy and investment program is successful and delivering results. In the third quarter, we completed approximately 61,500 clinical cases, up 21% year-over-year. This is our second consecutive quarter of accelerating growth, up from 15% in the first quarter and 18% in the second quarter. And we expect the momentum to continue as the commercial platform expands and new members of the Salesforce season. With respect to the pipeline, CARES Detect launched this summer, and CARES Assure Therapy Response Monitoring launched this quarter. As a result, as illustrated on slide 4, our platform now spans the entire continuum of care, including therapy selection in tissue and liquid biopsy with MI CancerSeq and CARES Assure, respectively, Therapy selection in hematological cancers with ChromaSeq, CARES detect for MSED, CARES assure for monitoring. And CARES Confirmed for MRD. We're very excited about the initial assay in our MRD product suite, CARES Assure, for monitoring. Monitoring is highly important clinically to provide oncologists a quantitative measure of treatment efficacy. The elegance of our technology is that it utilizes the same product platform as CARES Assure Liquid Biopsy with the same whole exome 23,000 gene platform. And the same liquid workflow our customers already use for therapy selection. The serial blood draws using Assure provide us with a consistent longitudinal view of cancer progression during treatment and will add another valuable edge to our clinical genomic dataset. CARES confirm our tumor-informed whole genome approach to MRD is on track to launch this September. Our clinical customers are excited about the launch of both of these products across the continuum of care. We get significant leverage from our commercial channel since each of these MRD products will be provided to the same institutions, the same oncologists, and the same patients that use us for therapy selection. Finally, our MSED platform, Keras Detect, has been the vision of our founder for many years, and the recent launch of Detect continues to build momentum. The unique multi-omic approach of Detect has produced exceptional early-stage sensitivity and is being well-received by the market. The channel partner conversations from digital platforms to concierge medicine groups are going extremely well. We launched our first consumer campaign in the third quarter featuring Kevin Costner and our second recently with Jordan Spieth to raise the awareness of the importance of early-stage cancer detection and of Karis Detect. We're excited about our data and studies, and SPETS will outline that, including the expanded ACHIEVE program. Our philosophy continues to be a long-term strategic orientation to develop the best, most comprehensive offerings on the market, and to pursue that innovation while maintaining financial strength. We had a strong third quarter with total revenues increasing 27% year-over-year to $275 million. As illustrated on slide five, This is driven by molecular profiling services revenues of $262.7 million, also up 27%. I'd point out that the prior year quarter also included a significant amount of true-ups, and as a result, on a pro forma basis, revenue grew approximately 45% year-over-year. So, in summary, we had a very productive quarter, illustrated by the quarter highlights on slide 6. Strong revenue performance, combined with the operating leverage in our model, continued to produce positive financial results while we step up investment, including revenue growth of 27%, driven by clinical volume growth of 21%, and a blended ASP of $4,272, up 5% year-over-year. On a pre-tru-up basis, our blended ASP was approximately $4,000, up 19%. We invested significantly this quarter while maintaining financial discipline. Adjusted EBITDA was $44.4 million, our sixth consecutive quarter of positive adjusted EBITDA, and we returned to GAAP profitability with net income of $15.3 million. Year-to-date, adjusted EBITDA is $126.3 million. Our balance sheet remains strong, with cash and investments of $769 million at quarter end. We believe our financial performance continues to give us unique strategic flexibility, which supports our ongoing investments in the product pipeline as well as the continued expansion of our sales organization. So with that, let's turn to commercial performance. The commercial strategy and leadership we established in the first quarter is delivering systematically. As slide 7 indicates, clinical case volume has grown every quarter this year. From approximately 52,800 cases in the first quarter to 59,200 in the second to approximately 61,500 in the third, and year-over-year growth has accelerated each quarter this year from 15% to 18% to 21% respectively, and we're pleased with acceleration in growth in both tissue and blood. The commercial strategy is working, and we expect to see ongoing growth acceleration. For a variety of reasons. First, the therapy selection market remains rich with opportunity as cancer centers implement systematic precision medicine programs. The institutions and the individual medical oncologists greatly appreciate the breadth and depth of the CARES product technology, i.e. 23,000 genes. And we expect that a recent launch of monitoring and upcoming launch of MRD will greatly enhance both our volume performance and also our appeal as a strategic partner with a technologically superior product line across the care continuum. Finally, we have exceptionally strong cancer-centered relationships, and the investment in FTEs will continue to help us activate more medical oncologists across our broadening product line. With respect to the commercial team investment, we ended the third quarter with 325 commercial team members, up from 290 at the end of the second quarter and 270 at the end of the first. We completed the realignment in January, expanding from 82 to 146 territories, and we've continued to add reps against that structure. Typically, new reps take six to nine months to begin to reach full productivity, so the hires we've made through this year will continue to build towards their full contribution for some time. We believe that we have the best technology platform, and accordingly, we intend to continue this commercial investment plan to provide this broad product line to as many medical oncologists and institutions as possible. The digital footprint continues to expand as well. More than 75% of orders are placed through EMR and portal channels, with more than 3,500 physicians ordering directly through the EMR. We're making investments in research and studies, and our body of evidence now exceeds 1,300 publications and manuscripts. Our business model is very powerful. With every clinical case profiled, our data set grows in size and power. As Slide 8 indicates, our data set has surpassed 1.2 million profiled cases, including more than 796,000 whole exomes, 849,000 transcriptomes, with approximately 845,000 matched cases with clinical outcomes. We are currently evaluating AI partners with respect to both internal capabilities as well as external data partnerships. We are as excited about the prospects ahead of us as we have ever been. As illustrated on slide nine, our company's positioning is highly differentiated against huge market opportunities and demand. The Keras molecular technology features uniquely powerful breadth and depth, which is now being extended to new product modalities. We have an innovative go-to-market approach as both a clinical partner and a research partner. The CARES Precision Oncology Alliance, for example, is now up to 102 sites, and we have important strategic flexibility, given our profitability, which will enable us to continue to invest aggressively. We have exciting and significant catalysts ahead of us over the next few quarters, which offer growth and TAM expansion, ongoing commercial execution and investment, ASP expansion through Assure, A pioneering role in the MSED market, the recent launch of monitoring, and the upcoming launch of MRD. I'll now turn the presentation over to Dr. Spetzler. Spetz? Thanks, Brian.

I will walk through the two new products and then the foundation model behind our digital AI platform, our planned expansion of our Achieve program for CARES Detect, and we'll close on interception. Everything I'm about to talk through comes back to what David said at the open, deeper, not cheaper. Depth and breadth are what allows us to complete a comprehensive approach across the patient journey, from early-stage detection to therapy selection and now monitoring and MRD. Slide 11 frames the two launches of the fourth quarter together. KERIS Assure Therapy Response Monitoring, which launched recently, covers the patient on therapy. CARES Confirm, launching in December, covers surveillance after treatment. Both are built on platforms we already run. Monitoring sits on our whole exome platform. CARES Confirm sits on our whole genome platform, with the initial tissue sample to define the signature, then follow-up testing in blood. Each has its own evidence base. Monstar and our real-world cohort for monitoring, Ensemble and the real-world cohort for CARES Confirm. Reimbursement work is underway on both, a Moldex submission and preparation for monitoring, and a cancer type by cancer type strategy for CARES confirmed. And I will discuss each a little more. Let's start with CARES Assure Therapy Response Monitoring, which launched recently as part of the upgraded CARES Assure platform. For therapy selection, Care is Assured tells the oncologist which drug to choose. For monitoring, the same whole exome liquid workflow with matched Buffy code to remove clonal hematopoiesis gives a quantitative tumor fraction, and serial draws classify the patient as a molecular response, stability, or progression. The readout arrives roughly four to eight weeks ahead of the scheduled scan. The validation is on the slide. Clinical validation included 124 serial pairs, and in the 90-patient landmark cohort, 96% of patients classified as molecular responders went on to show disease control on imaging, 49 out of 51. Patients classified as molecular progression had a hazard of subsequent radiographic progression nearly nine times higher than responders, 8.99, or 7.16 after statistical adjustment. And in an early, independent, real-world cohort of 1,037 patients, molecular progression carries a 2.35 times hazard versus response, with the three categories separating in order. Analytically, the assay detects tumor fractions down to 0.1%, with precision under 9% CV across lots and runs. Moving to slide 13, CARES Confirm is our entry into minimal residual disease and is currently planned for launch in December. The approach is tumor-informed and whole genome. We sequence the tumor and a matched normal across the entire genome to find a patient's set of trackers. A tracker search space of roughly 2.5 billion bases. We then track those variants in serial blood draws on the same whole genome platform that Powers Keras detects. The pathway is relatively simple. A baseline blood draw with butt to coat plus tumor tissue from surgery. Tumor normal subtraction to define the patient's tracker set, a landmark blood draw three to six weeks after surgery, and then surveillance draws every three to four months. That is what gives us an ultra-low limit of detection by design. The analytic performance speaks for itself, with a minimum positivity threshold of 1.38 parts per million. The intended use is PAN tumor, stage one through three solid tumors after curative intent treatment. A setting where patients are monitored for years. So like therapy monitoring, this is a reoccurring test on infrastructure that is already in place. Moving to slide 14. This is our engine under our digital AI platform. HERO is our pathology foundation model. It was trained on 248,606 routine H&E slides across 52 cancer lineages, and 98% of those slides, more than 243,000, also have RNA sequencing alongside DNA sequencing and IHCs. Please. That pairing is the acid. The molecular results give us every slide it's labeled. The process runs left to right on the slide. The H&E is scanned at 20x. The tissue is cut into tiles about a tenth of a millimeter across, roughly 2,300 per slide. HERO describes each tile as 3,072 separate numbers, the same for every target, with no retraining. For each target, the model learns how much each tile matters and weights the tiles into one summary of the slide, and from that, three models, one for each of DNA, RNA, and IHC. Predict 297 alterations, 368 RNA expression levels, and 21 protein stains from the same slide alone. Our model powers Keras digital AI applications. That is why the pipeline on the right, morphological subtype, tumor grading, mutation prediction, treatment response, and survival prediction can move quickly. Each is a new head on the same foundation, trained on data we already have. Now, let me turn to CARES Detect. As we've discussed before, slide 16 shows why we built CARES Detect to combine many signals across cell-free DNA and RNA, expanding our shots on goals across each early tumor. Moving to slide 17, Achieve 1, the basis for our commercial launch, showed 99.2% specificity and 60.3% sensitivity in stage 1 and stage 2 cancers, the stages where the cure rate is highest, and I will give an update on our planned next readout from Achieve 2 in a few moments. Now, as part of this quarterly update, I will provide an update on our Achieve program. As you know, this is the clinical evidence program behind CARES Detect, and one that we are announcing an expansion to, with four studies under the Achieve name, totaling 63,000 patients. Achieve 1 is the 3,000 patient study you just saw. That readout was delivered in the first quarter. Achieve 2 is our large-scale validation with a target of 25,000 participants. We have enrolled approximately 20,000 patients, 80% of the way there, and we currently expect an interim readout in Q1, 2027, as we have begun to run these samples. Achieve 3 is a 10,000-patient prospective study in a high-risk population with results returned to patients and a repeat Keras detect at 12 months. And Achieve 4 is a 25,000-patient prospective study in a general risk population, also with results returned. Achieve 3 and 4 are in planning now. And on slide 19, as DDH discussed, we have launched two campaigns for CARES Detect, and both point consumers to CARES Detect, and these will continue to be rolled out across markets into Q4 and beyond. Finally, personalized mutation interception. We outlined this program on our last call, so today I will keep it brief and focus on how the pieces of our platform fit together to support it. As a reminder, our personalized vaccine approach is built on capabilities we already run. Keras detect finds the early signal, our sequencing defines the mutations that inform a personalized vaccine, and serial blood draws track whether it is clearing. Slide 21 shows the step where our platform is most differentiated, choosing the right mutation. We select only the mutations that are expressed and visible to the immune system as vaccine and targets and tracked response over time. This is where our data set does the work. Our ranking model achieves 83.8% positive predictive value and 86.5% for the top-ranked variant per patient, measured against a paired biopsy cohort of more than 42,000 patients. So we focus on the mutations most likely to prime a response. So that is the focus of our science. Two new reoccurring use products on the platform, a foundation model that lets a digital AI portfolio grow quickly, detection that is both broad and precise, with an expanded 63,000 patient evidence program behind it, and an interception strategy that is novel, all resting on the depth-first approach. With that, I'll turn it over to Luke.

Thanks, David. I'll move relatively quickly through the numbers since we have touched on some of them already. We delivered another strong quarter with total revenue of $275.4 million, which is up 27% year-over-year, and brings our nine-month revenue to $755.2 million, which is up 45% year-to-date. Molecular profiling revenue was $262.7 million, up 27%, and pharma research and development services revenue was $12.7 million, up 37% year-over-year. As we have expanded our platform this year with new products and with MRD planned for launch later this quarter, we'll be moving to reporting total clinical volume only. This is consistent with how our sector reports and is the basis of which we'll report our preliminary full-year volume in January and provide guidance numbers going forward. That said, I'll provide a little bit more context around the current quarter volume numbers. Clinical therapy selection volume in the third quarter was approximately 61,500 cases, up 21% year-over-year, ahead of the 20% milestone we outlined for the quarter. This volume excludes CARES Detect, whose revenue we will report in our pharma research and developmental services line until it becomes material enough to break out along with its volume. Therapy selection remains the core of our current volume, and in the two quarters since the Q1 sales realignment, volume has grown approximately 20% year over year, and we're encouraged by that momentum heading into Q4. Therapy selection volume mix was in line with the trends from the past two quarters with tissue remaining the core. Both tissue and blood saw an acceleration in year-over-year growth rates from the second quarter, and our overall growth rate of 21% was the highest it has been in over a year, and is a testament to the great work being done by our sales and lab teams. For CARES Detect, we're pleased with the initial rollout, and we're continuing to expand our marketing, with two campaigns now running, and we'll be expanding markets as we progress into Q4 and beyond. Moving to gross margin, this was 66% in a quarter, reflecting the mixed impact of our expanding product portfolio, and we expect a similar level in Q4. That also reflects our focus on deeper, not cheaper, and you can see that by our recently upgraded Cars Assure Assay, which is now running on the Illuma NovaSeq X platform with increased depth and reads. Operating expenses were $163 million, up $48.1 million year-over-year, and about $10 million sequentially. That increase was in line with our expectations as we continued to invest in the commercial organization, along with increased marketing dollars for CARS Detect and the development work on therapy response monitoring and CARS Confirm. Overall, these results produced GAAP net income of $15.3 million compared with $24.3 million a year ago. Year-to-date, net income is $14.1 million, against a net loss of $150 million the first nine months of 2025. Adjusted EBITDA was $44.4 million, our sixth consecutive positive quarter, compared with $51.2 million in the prior year, which again carried a larger true-up benefit. Year-to-date, adjusted EBITDA is $126.3 million, up from $31.7 million for the same nine months last year. Free cash flow was negative at $39.7 million in the quarter and included $17.5 million in capital expenditures. As we communicated in August, this was planned as we used the free cash flow generated in the first half of the year to fund the rampant inventory and the initiatives behind our pipeline. And you can see that in the working capital movements on the balance sheet. Through nine months, free cash flow is negative at 10.8 million, and with that inventory investment behind us, we expect to return to positive free cash flow in the fourth quarter and for the full year. We ended the quarter with 769.2 million in cash and investments, and we repurchased approximately 10 million of additional stock under our authorized share repurchase program in Q3. Moving to slide 24, we continue to demonstrate strong growth across volume and ASP within our molecular profiling business. Blended ASP, base ASP, surpassed $3,990, up 19% year-over-year, and including prior period collections, blended ASP was $4,272, up 5%. On the reimbursement front, we received the preliminary 2027 clinical lab fee schedule under PAMA cycle in September. My CancerSeq was maintained at $8,455. However, CARES Assure was increased to $5,250, up from $3,650, and this is effective January 1 of 2027, subject to the final schedule later this year. This will also have a positive impact on the commercial contracts we've been signing, as they are generally priced as a percentage of the clinical lab fee schedule rate. So the higher rate should lift realized ASP across the contracted book as we move into 2027, and that is the covered life strategy we described last quarter. We also received our first commercial plan payments for CARES ChromaSeq. And overall, now, covered lives stand at approximately $264.4 million for My CancerSeq and $134.6 million for CARES Assure, both up again from the second quarter. Finally, turning to guidance, given the strength of our first nine months, we're raising our full-year outlook range to approximately $1.04 billion to $1.05 billion, up from $1.03 to $1.04 billion, representing growth of approximately 28 to 29 percent, driven by molecular profiling Thank you. Including prior period true-ups, the guide implies four-quarter growth in the 40% range, consistent with the underlying rate we delivered this quarter. On a reported basis, our four-quarter guidance range of 285 million to 295 million is broadly in line with the four-quarter of 2025, which included roughly 90 million of true-ups due to the acceleration we experienced last year from our My Cancer Seek FDA approval. For the fourth quarter, we also expect clinical therapy selection volume to continue on the growth trend demonstrated the last couple of quarters and to be approximately 60 to 5,000 cases and result in approximately 20% growth for the full year. We now expect GAAP operating expenses of approximately $620 million up from approximately $600 million or a growth of approximately 26%. That increase is deliberate. It funds the expanded commercial organization. The marketing behind CARES detects, therapy response monitoring, and CARES confirm, along with processing of the R&D samples for the Achieve II interim readout. And we continue to expect both positive adjusted EBITDA and free cash flow to be positive for the full year. Just an EBITDA is already $126.3 million through nine months, and we expect free cash flow to return to positive in the fourth quarter, bringing the full year to honestly positive, all by funding our growth initiatives that we just walked through. With that, I'll wrap up the presentation and turn it back to the operator and open it up for questions. Operator?

Thank you. If you would like to ask a question, please press star 1 on your telephone. You will then hear an automated message advised when your hand is raised. If you would like to remove yourself from the queue, please press star and want to gain. We also ask that you please wait for your name and company to be announced before proceeding with your question. One moment while we compile the Q&A roster. First question will be coming from Vijay Kumar of Evercore. Please go ahead.

Hi, guys. Thank you for taking my question. That's a nice sprint here. Luke, maybe my first question for you on, you know, I know you mentioned both tissue and blood volumes accelerated, but maybe if you could just give a little bit more color on the pace of acceleration, you know, tissue versus blood. And a similar sort of commentary on ASPs, please, where did the increase come from? I know ASPs were up 19%.

Yes, yes. So, Vijay, like as we said in our remarks, we won't be breaking it out separately going forward, but what I can say and what I disclosed is the mixed trend is consistent with what you saw from Q1 to Q2. So blood continues to grow and tissue continues to grow. So the growth rates increased from what we reported last quarter, which is excellent and in line with our expectations, and I think we can continue to over-deliver on that as we progress into Q4. From an ASP standpoint, again, similar to last quarter, from a blended ASP, we continue to see strength in what our market access teams and our billing teams are doing. So we've had success across both cars to shore and by cancer seats continuing to get coverage there. So, for us, our expectation is that's going to continue to improve into the fourth quarter. And with the guidance that we put out, you're in a similar range of around that 4,000 base ASP, which would be a new record for us. So, overall, I feel great, but the mix and everything is going according to plan.

That's helpful. And maybe a big picture question. If I just look at how the uterus progress, right? Volumes have accelerated every quarter, and your fourth quarter guidance implies another step up to maybe perhaps 23 plus on clinical volume growth. So when you look at the progression and the fact that you have new test launching, should 27 clinical volumes accelerate from 26 levels of 20 percent? Would that be a fair assumption?

It's a fair assumption. What we're not doing right now, though, is guiding to 2027 volume. The key for us coming into this year was kind of twofold. One was obviously doing the expansion in the commercial org, but the second was pushing out the pipeline as quickly as possible. Because we have unique tests and because they're the most comprehensive, we wanted to get through the end of the year with all those tests on the market, which is what we're striving for and will accomplish. So we feel very good about that. I think as we start looking towards 2027, the key for us was correcting the therapy selection growth, and we've seen acceleration both in tissue and blood this quarter, which is great. It shows the commercial plan is paying off. And then as we progress into next year with the rollout of monitoring, with the rollout of confirm, we'll do that in another disciplined, diligent way as we work through the reimbursement pathways, but it definitely should contribute on the top line because it's the existing sales force selling the products.

Thank you.

Thank you. One moment for the next question. Our next question is coming from the line of Subunambi. Please go ahead.

Hey, guys. Thank you for taking my question. ChromoSeek and MI Clarity now have about two quarters of commercial history. Are they in the updated guide? How did each ramp in the quarter, and when do they become meaningful contributors?

And they're, yes, so they're smaller, they're obviously a smaller portion, and that's why I referenced them. We're mostly not at the same scale as what we're doing with a tissue.

I was trying to get at when do they become meaningful contributors, and I also have a follow-up.

Yeah, I think as we progress into the end of the year and into next year, you'll start to see AEM continue to grow along with myclarity. I think right now, as we're looking at the guidance for the remainder of the year, they're not material compared to blood and tissue.

Got it. So think of it as more 27 rather than this year. On the enhanced CADIS Azure that adds the track table for response monitoring, you plan to pursue MoldiX reimbursement for it. When do you plan to submit to MoldiX and do you have the data that you need or you're still generating it?

Do you want to take that one?

Yeah, we've completed the trial, so we're working on that submission now. It should happen in the next several months. We need to publish it first, and it's always hard to predict how long the publication process takes.

That's fair. And last one, what percentage of blood tests were attached to tissue tests in the quarter? You've always hovered around 30%, 40%. Should we expect the same thing, Or have you seen that attachment grow meaningfully?

We've seen it grow, and probably not meaningfully. It has increased past 40 percent, so it's been at 42 percent for the TURC order, but not materially past that.

Perfect. Thank you, guys.

Thank you. One moment for the next question, please. Our next question will be coming from the line of Lully of Bank of America.

Great. Thank you for taking my questions. I guess I wanted to clarify, the CARES detect is now in the R&D line, the fiber R&D line. Is that true also in 3Q? And then also related questions to that. So in terms of the 4Q guide, like how do you kind of like break out between the profiling business and then also the R&D? Any assumption will be great.

Yes, so detect will be reported in there until we have a couple of more quarters. It's consistent with what we've kind of disclosed in the past with any new product launches. We'll continue to monitor it about when it becomes material. It was small compared to the relative 275 million we put up, so we haven't broken it out yet, but we'll continue to obviously feel really good about where it's going. I think as you look forward to Q4, it doesn't include any of the new products. We'll continue to do that from a guidance standpoint. We always like to wage a couple of quarters before we start looking at including additional new products in there. So the breakdown for Q4 is effectively about $265 million for molecular profiling, and then the range of $20 to $30 million for pharma, and that doesn't include any detects.

That's very helpful. And then on the MRD launch, I'm wondering, can you just like talk a little bit about your reimbursement process, definitely like cancer indication by indication, but do you have like any timeline in terms of like when are we going to see the first indication reimbursement? Thank you.

Do you want to make that submit?

Sorry, Ken.

Yeah, it's kind of the same. So we've completed our first trial, need to publish that one in colorectal cancer, and then we'll be able to submit to Moldex.

So, I guess we'll be kind of like 2027 will be, sounds like, good timing.

Yes.

Okay. Thank you.

One moment for the next question. Our next question will be coming from the line of Adam Weishaus of UBS. Please go ahead.

Thanks for taking my question. You mentioned that a share is going to move to the higher CLFS rate in January. I'm just curious, how are you thinking about that magnitude and timing of the benefit to realized AFP in 2027, particularly as you've mentioned, commercial contracts are generally priced as a percentage of that CLFS rate? Thank you.

Yeah, Adam. Yeah, so we feel actually excellent about that. It should be pretty immediate for, especially for the contract that we've signed and obviously for Medicare itself. So for Q1 and Q2, we would expect to see the bulk of the step up there. We continue to make progress with other payers where we're not covered right now, and obviously that proposed increase that will come into effect January 1 will also help with those negotiations. So, we would expect it to be a kind of Q1 and Q2 impact, primarily Q1, though.

Thank you.

And you also mentioned that the tech interest remains ahead of expectations, but you don't intend to chase demand by overspending. So how are you measuring kind of response to the initial rollout and deciding how aggressively to scale that investment up?

Yeah, it's similar to how we approach everything. And when we say disciplined, like what we want to do and one of the unique positions we're in is obviously we're funding all these initiatives ourselves. The free cash flow negative was a one-time event because we did that initial inventory purchase and we feel great about how the tech is going. So what we're doing is we're continuing to assess obviously what our partners to pull through and we feel good about that. And we're continuing to expand the partnerships as well. So we'll work through that in Q4. Also, with the actual ad campaign, we launched that in selected markets. We haven't broadly launched it fully yet, and we'll continue to assess that on a quarterly by quarterly basis. One of the key things, and we said this on last quarter's call, is We're always aware of kind of the potential for this test and the capacity constraints on it, so that's why we're taking the disciplined approach with rolling it out market by market, and we'll continue to assess that as we go into the end of the year and next year.

Thank you. Thank you. One moment, please. Our next question will be coming from the line of Casey Woodring of J.P. Morgan. Please go ahead.

Great. Thank you for taking my questions. I guess the first one, can you just elaborate on the MSED launch, and if you can get specific, you know, how many MSED tests did you sell in the quarter, and I guess what's baked into the 4Q guide?

Yeah, Casey, there's nothing baked into the four Q guides, and right now, as we said in the prepared monarchs, we're going to include it in the research line until we have more and more activity flow through. Before we break it out, we'll continue to assess that, but there's nothing in the guide for Q4.

Okay, understood. And then I think if I'm doing the math right, pharma R&D 4Q revenue is something in the $20 to $30 million range. I guess that implies a pretty big cut to the full year number. So maybe just walk through kind of what you're seeing in the pharma R&D service business to end the year and expectations for that business line moving forward. Thank you.

Yeah, yeah, so Casey, so you've seen the trends, like, since the beginning of the year. That's also improved sequentially from a revenue standpoint. And it's a business that we've obviously not been focused on in the past, but we're starting to gain traction. And one of the key things that we were focused on coming into the year is not focusing on smaller deals, but more larger long-term deals. And the sales cycle for those continue to be kind of a little bit longer. But going into Q4 with that guidance, we feel really good about that stepping up to over 100% growth. And we think we can maintain that momentum then as we continue to build out the team into 2027. I think from an overall standpoint, we feel really good about where our revenue at is on a total basis, and that's where I feel confident, obviously, with the guidance, and that's why the only range is around that pharma, because we have a couple of deals working through the pipe, and it's more of a timing issue.

Understood. Thank you.

One moment for the next question. The next question will be coming from the line of Albert

Hu of City. Perfect. Thanks for taking the question.

So maybe just jumping off Casey's question on MSED. So you guys currently have that in the pharma R&D side of things. So when do you guys expect volumes for MSED to really ramp up here? Is this going to be like a... Do you have the 2028-2029 situation when the reimbursement likely comes on, or how are you guys thinking about that going forward? Appreciate it.

No, again, Albert, like, what we're doing with MSED, it's self-pay, it's direct-to-consumer. So it's different from what others are doing, because one of the key reasons we're doing that is we want to make sure it's focused on the technology. Like, technology should drive, obviously, the science, and it should drive how you approach the market. So that's one of the differentiation factors here versus all the other approaches that are out there that are utilizing the same sales force going to PCP. So we do expect it to continue to run. And again, that's dependent upon how quickly we want to put our foot on the gas from a campaign standpoint. And that's where we said in the prepared remarks, we're not going to overspend by doing this, but we're going to do it smartly. And we feel really good about where it's at today. That increased penetration that we're seeing, so I would expect it to continue to ramp throughout the next couple of quarters, and again, we'll assess it as we get into 2027 how much we want to spend on the ad campaign, but we're going to be smart about it.

Okay, that's helpful. And then maybe as a follow-up, So last quarter, you mentioned that, you know, there are some sequencing competitors out there with higher throughput, with lower cost compared to the dominant supplier that you guys are on right now. So is there any sort of switch in process for you guys that's happening, a.k.a. do you expect Cox to come down further because of this, or what's the thoughts on Cox going forward? I appreciate the question.

Yeah, yeah. Like, I definitely think there's opportunity on the COGS front. I think we're, we stated this on previous earnings calls, we're technology agnostic. I think more competition is better, and we continue to assess. So there's definitely opportunity as we progress into 2027 and beyond, and it's going to continue to come down. So, but again, our focus right now is to create the best technology, not focus on cost. You see that from our next. Our upgraded version of Parish Assure. Like, again, we went deeper, not cheaper. We could have made that and improved the margin. But again, we want to get the data. We want to ensure it's the best test on the market. So we always utilize that approach before we actually start focusing on the unit economics. But I think as we progress into 2027 with all our tests on the market, that's where you'll start to see the benefit flow through the margin. And we feel pretty confident about that regardless of supply vendor.

All right. Thanks so much.

Thank you. One moment for the next question. And our next question is coming from the line of Mark Mazzaro of U.S. Bancorp, TBIG.

Hey, this is Megan. I'm from Mark. Thank you for taking our questions. So following the positive FDA adcom, we'd be curious to learn if that might give you any desire to pursue FDA pathway and approval for DETECT.

Yeah, I definitely, yeah, go ahead.

You can do it, Luke, it's fine.

Yeah, I definitely, like, obviously, I definitely think we consider it, but as I previously just stated, too, I think our focus is always going to be on the technology first, rather than the FDA pathway in order to secure reimbursement down the path. But I think... If you focus on reimbursement initially, it could limit the kind of performance of your test because you're trying to create a test inside a particular margin. Again, that's not of our approach, so the FDA is not in our near-term future for that, but again, we'll continue to assess the overall macro environment as it progresses over the next couple of years. But right now our focus is on obviously returning out the Achieve II interim readout in Q1, hopefully early Q1, and then completing that study and then expanding with what Dr. Spetzer said about the Achieve III and Achieve IV to show the continued performance of a whole genome approach, which is unique. So I think that's more our strategy right now around the trials. We'll assess the FDA pathway as we progress through that.

Understood. Thank you for that color. And then we were also, again, on CARES Detect, it was nice to see the ad campaign launch. So just curious if you have any color on the feedback of the launch and, yeah, anything you've heard that can speak to that.

Yeah, it's been, feedback has been positive. Again, it's a unique approach. I think people appreciated that. That's some of the kind of key feedback we're getting. The performance in stage one and stage two is obviously. The best key metric for any early stage detection test, and that's why David said in the opening, too, that's our focus. It's early stage, stage one and stage two, where you can make a difference. So I think there's been a positive response to that. Again, we're being disciplined with how we roll this out, and we're going to continue to increase the marketing behind it, but not overspend, as David said in the opening. So it's been positive. We'll continue to assess, and then we'll continue to monitor it going forward.

Great. Thank you, guys.

One moment, please, for the next question. Next question is coming from the line of Dan Brennan of TD Cowan. Please go ahead.

Great. Thank you. Thanks for the questions. I joined late, but I think I'm caught up. Maybe just on the fourth quarter volume guide, the 65,000, which is consistent. I know there is a step up there. You've got the expanded sales force, which you guys must feel good about, but is there a cushion in that number since the number this quarter was just about what you guys expected on the volume side? Price was a big upside driver. So just thinking about the fourth quarter volume, how do you guys feel about that?

I feel very good about that. So, obviously, we'll guide to what we expect the numbers to be. So, the 65,000 is the expectation along with that. Because it flows with our plan at the beginning of the year, which obviously we beat, again, by a percentage point in Q3, but we continue to assess and we continue to believe that 20% is kind of the guide number for now. I definitely, as we progress throughout the quarter, we feel very positive about our volume numbers.

Thanks, Luke. And I think there was a question I asked earlier about... Potentially 20% volume growth in 27. I know you guys aren't guiding, but at the same time, I know you've also talked about taking a conservative stance when you get to the point of guiding. So any way to think about, like, will there be some natural kind of cushion that you do bake in for next year, or is your point you're just going to, you know, use this year's, you know, number and just kind of roll that forward?

Yeah, we'll assess that at the end of the year. I definitely think we could look and see where we're at with the new launches. We feel really good about them, especially monitoring and MRD coming down the pipe. So I think as we get into next year, that's where we'll focus on, okay, what are we going to guide to from the new products? Where do we feel like the therapy selection business is? And kind of assess it that way.

Got it. Got it. Yeah. So basically, if, you know, if there is a 20, whatever the number is, it's going to incorporate, it'll have therapy selection plus these others in there. But will you break out therapy selection in the guide when you do it?

No, I think what we'll do as it grows, we'll continue to assess it. But I think initially we'll take the path that we're taking right now, where it's a total clinical volume number.

Got it. Okay. And you guys didn't give an M-set number this quarter. I know it was asked three or four times, right? Was there a number given or no? No. No. No. Okay. All right, guys. Thanks a lot. Appreciate it.

One moment, please, for the next question. Our next question is coming from the line of Evie Koskloski of Goldman Sachs. Please go ahead.

Great. Thanks for taking my questions. So first, maybe talk through your conversations with health systems ahead of the Confirm MRD launch. Maybe how much appetite is there to simplify suppliers from their perspective, given, you know, you have the full portfolio of tests, and maybe also talk through the performance of the test versus peers in the face and generally how you're viewing the competitive environment.

Yeah. Brian, do you want to take the customer focus and then- Hey, yeah, hey, hey, hey, Evie, hey, it's Brian.

Look, our institute, we have very strong and very broad institutional and individual medical oncologist relationships that in many respects- We have anticipated the rollout of our technology, whole exome, whole, you know, 23,000 genes across a broader product line. So there's an embedded demand on the part of all of these relationships for an MRD slash monitoring type of solution. So we expect... We expect that introduction. I wouldn't even call it a launch. I'd say it's an introduction and provision of the Keras platform more broadly across those same institutions, same oncologists, and in some cases, you know, same patients. So I'm very excited about that. It will help us in terms of volumes. It'll help us in terms of just our presentation as a strategic partner. It fits neatly into those conversations at both the senior leadership levels at the institutions as well as with the individual medical oncologists. So I'm very excited about that. I think the differentiated technology is super exciting as well as just the completion of the continuum of care. So that's, you know, that's how we feel about it. And I think it's just a very natural thing for our existing sales force to have in the bag. Now, we'll probably, just like with CARES Assure, you know, this fits within the specialty sales team for Assure, which we're continuing to build. So as part of the investment program, more FTEs within the sales force. We're also building out the specialty team. So I think that's going to be part of the

And then on Detect, I know you mentioned the advertising campaigns were really only launched in a few markets. I guess when should we expect you to get to kind of the full 100% launch of those campaigns? And then also maybe talk about the global opportunity within Detect versus more of the U.S. opportunity and where you would expect to see the initial demand there.

Yeah, so I can take that, Evie. So I think what we'll do is we'll continue to be kind of assessing it as we continue to roll out and make sure we have enough capacity for running it. Again, it's a differentiated asset. Assay in its whole genome, so it's a lot of sequencing. So we'll continue to assess that from the capacity front with the rollout, and then that will align with how we do from a marketing standpoint and continue to expand markets there and expand into partnerships there. You're 100% right. Obviously, we're focused on the U.S. market right now with the digital platform. I think there's a huge opportunity to expand. That's not in our plan right now. In the next couple of quarters, we're focused on the U.S. market, but there's definitely opportunity as we get to the end of 2027 to start considering additional strategic partners outside of the U.S.

I mean, we've had significant reach out from large groups. Outside the United States, more generally, but also as it relates to detect and MSED. So I don't think it should be a surprise that there's strong interest. You know, in longevity, healthspan, and MSED, as well as our technology as it relates to Keras Detect. I think the other thing worth pointing out, you know, we've talked a little bit about the technology and the campaigns, but the other thing that's going on that we're spending a lot of time and effort on is building the channel. So, as you know, we're not taking a, you know, individual PCP type of approach, But rather developing strategic relationships with channel partners that often have organized the PCP. So we're working with the digital platforms, concierge medicine groups, longevity companies, et cetera. And this market... is scaling very rapidly, very significant membership, and they're looking for a solution. They're looking for the best technology. They're looking for MSED as a part of their overall strategy, and they want a better MSED solution than what's currently available. So I think we, with our early-stage sensitivity, fit very neatly within that. We have many conversations going on. They're all positive. And what's happening, I think, to be more specific about it is we're developing those relationships, and we're getting onboarded, right? In many cases, they have SADs. They have a process. So we're getting onboarded. They're very interested in the technology. So all of that is building, and I'd say there's a lot of momentum as it relates to kind of onboarding those various channel partners.

Great. Very helpful. Thank you.

One moment, please, for the next question. Our next question is coming from the line of Taisho Peterson of Jefferies. Please go ahead.

Okay, thanks. Thinking about just care for therapy monitoring, how should we think about, you know, the attached rate with therapy selection testing? I mean, is there a general rule of thumb that you're keeping in mind as you roll this out? Is it, you know, two to one? How do you think about that?

Brian, do you want to take that one?

Listen, Tycho, that's a great question. We think it's going to be quite significant because it's very natural, given the interest in our technology, to follow through with monitoring. So I don't think we have a specific answer to that, but we think that given the initial reaction and just the logic associated with this, we think that attach rate could be quite significant.

Okay. And then one for Luke on margins. I mean, just thinking about the gives and takes here. I mean, you're rolling out three tests, you know, without reimbursement out of the gate. Obviously, detect is cash pay, but then you have the Everly Well partnership, so splitting the economics. Can you maybe just, you know, get us comfortable with the margin outlook? I know you don't want to talk a lot about 27, but how do we get comfortable, you know, it's not dilutive to margins significantly as you roll these out?

Yeah, again, it's because of the discipline approach we'll take, Tyco, with everything. So one of the key things that we'll continue to assess is obviously the improvement in sequencing technology, which I think will benefit. It was a question asked earlier. We're definitely seeing that play out, and we definitely think that will have a positive impact on our existing products today and on our new products as well from a sequencing cost standpoint. I think the second thing, too, is obviously we continue to execute across the billing and market access groups, and I think with our existing products itself and with obviously the increase in the 52-50 rate for CarSassure effective January 1, that will also help. Kind of soften the blow of launching these products without reimbursements, and that's kind of our plan, is to continue to manage it smartly. So I don't expect a massive deterioration as we go through this. And then I think actually we can see improvements on the sequencing technology. Obviously, if MRD is a very... We're recurring products that you could have a lot of tests out of the gates, but we'll launch this in a smart way with select customers and continue to roll it out customer by customer rather than a broad launch initially while we work through the reimbursement pathway. It's similar to what we're doing with monitoring. It's a similar approach. So again, we'll be smart about it. I don't expect massive deterioration at all.

Okay, I'll leave it at that. Thanks. One moment for the next question. The next question is coming from the line of Paige Chamberlain of Wolf Research. Please go ahead.

Hi, guys. Thank you so much for the time and the question. We're all clearly very focused on detect. I'm going to ask another one, if you'll allow it. If I'm recalling correctly, there was a comment on the 2Q call around current revenue capacity. I think it was specific to detect, and the comment was $1 billion in revenue capacity, which at a 3,500 ASP implies something like 300,000 tests. And I swear on all of that math and that volume number, you know, anything we should be thinking of in the ballpark, you know, anytime soon. Thank you.

Yeah, I think that's where we want the capacity to be, Paige. I think that's what we're striving for. You can see that reflective in our CapEx expenditures. It's one of the key things we're focused on as we roll out, not just the techs, but also the other products that are recurring, is increasing the sequencing capacity to support that potential. So, that's something we're working towards. It's not something we have today, but that's what we're working towards over the next couple of quarters and what you've seen over the past couple of quarters with our cap expense.

Awesome. Thank you. And I'm just going to squeeze in one more. On the Salesforce expansion, so I heard the latest number this quarter, 325. You must be liking what you're seeing because the original number I think you guys were targeting was 300. I'd love, you know, detail on, you know, what sort of metrics you're seeing that are, you know, encouraging the continued expansion. And is 325 sort of a stopping point? Or are you guys still hiring? Thank you so much. Yep.

Yeah. Hey, Paige, it's Brian. We are liking what we're seeing a lot. We have so many different things to work. We think the market's very accommodating. We see a large and growing TAM with increasing adoption of precision oncology programs as well as just more profiling on the part of individual medical oncologists. Our platform overall has many different edges from technology to scale. I think our channel itself with all the relationships is a huge competitive edge. But as you know, you know, the FTEs had drifted down there for a while, right before the IPO, so we're continuing to build in, and we're seeing a real ROI associated with that. And we don't see any end in sight for that, so we're going to continue to hire. Our chief commercial officer is organized. We're going to expand the number of territories. We'll expand the number of FTEs. We see the opportunity in the market. For sure, it's only growing, and we think we have a significant number of edges so that, you know, we don't see any reason to not continue to put the various pieces in place to provide the technology to more institutions and more oncologists.

Thank you.

One moment. The next question will be coming from the line of Jack Meehan of Open Research. Please go ahead.

Thanks for squeezing me in, guys. I wanted to ask about the volume question in a different way. Maybe out in that 61,500 tests that you reported, is it possible to tease out what non-therapy selection contribution there was? And the reason I ask is, building off Dan Brennan's question earlier, just looking at the sequential step up in 4Q, I assume that is expanding, so just getting a little color on how that is trending would be really helpful.

Yeah, Jack, so if you take, like, that's the reason why we commented on the mixed trend from the first couple of quarters. It's consistent with that trend, what you saw from Q1 to Q2, and then that following all the way to Q3. We expect that trend to continue into Q4.

Okay. And then, as an unrelated follow-up, I did want to ask you about the supplies on the balance sheet. Obviously, you did some stocking last quarter. It looks like you did more stocking this quarter. You know, the inventory kind of weeks on hand is elevated. Was curious, maybe just your philosophy around stocking, you know, why you're doing this and whether you think that could be a source of cash, you know, at some point.

Thank you. Yeah, again, it's ahead of the launches. One of the key things is obviously with the detect launch, we got prepared. But the other thing, too, is these are the same kits that we're going to run for Achieve 2 samples, which we started to run. So that's kind of a key focus for us in Q4, to get that interim readout as quickly as possible. And then also with the new Assure launch as well. That's on the Nova X platform as well. So I think what you saw this quarter with the inventory is just kind of a general step up. It's kind of consistent with what we've done before that big wrap-up in Q2. And, yeah, we paid down, obviously, quite a bit of it. You can see that reflected in the accounts payable. That dropped close to $38 million, and that was on purpose. So that's why we feel very confident about being positive free cash flow again. Again, we don't expect to do that ramp by the end of the year.

Thank you, Luke. Appreciate it.

Thank you. One moment, please. And our next question will be coming from the line of Cal. Mikeson of Canaccord. Please go ahead.

Hello, this is Alex J. Kaysen. I'm on for Kyle Nixon. Congratulations on the quarter and a recent test ologist. Thank you for taking your questions. So just circling back to the first question, the Q&A, understanding you aim to provide less granular detail in this going forward, one of the key factors that we continue to monitor going into next year is the tissue therapy selection test volume expansion. So you stated in a pair of remarks, Deputy selection opportunity remains rich. This will give you confidence you can continue to expand the base tissue aspect of this business going forward. Could it take additional commercial investment? And is mid-double-digit area test line expansion sustainable for the blood side of the deputy selection business in the near to medium term? Or could we perhaps see a bit of a slowdown? Thanks.

Yeah, I think like what we've shown is obviously the acceleration, and that was in our comments, the acceleration across boats from Q2. So that was positive, and tissue was obviously accelerating too, which is kind of our expectation with the investment that we're doing, but with the reorganization and the realignment. So I definitely think tissue will continue to improve into the end of the year. I definitely think it can continue to improve going into next year based on what we're seeing. I think from an overall standpoint, blood is obviously growing at a faster rate. It's starting from a smaller base, but we're continuing to see that growth and accelerate it in Q3 from Q2. So again, that's a testament to the work of the sales team. I think we'll continue to be added to the sales team. As Brian mentioned, we're not going to stop with the 325. We're going to keep adding based on what we're seeing from the inbounds and from the orders and from the penetration in the institutions. So we feel great about both going forward, but we won't be disclosing a growth rate for each of those individually. It'll be on a total basis.

Thank you. And so, you've obviously been able to achieve a lot of innovation internally, yet it's important to note that you maintain a substantial cash position which provides you with optionality. Could you elaborate on your M&A mandate or criteria? And generally, if you're open to acquiring technology externally, it's either boost current offerings, perhaps planned offerings for launch or launch products available commercially. Performance and competitive reasons or just to expand the test menu. Thanks.

Yeah, I know.

I was just going to say, look, this market has grown, and it's definitely consolidating, so there's more M&A, which I think is healthy because the number of these companies without a commercial channel really need to find a home. They have no real viability on a standalone basis, so there's plenty of opportunity. We have not used it as a tactic. For a whole variety of reasons, including the fact that we haven't seen anything that we thought would be incrementally helpful to us, particularly from a technology perspective. So, you know, our founder here is always focused on developing and pioneering this market and creating the best technology, and I think we're going to continue to do that. So with that mentality and with our leadership position, with respect to technology, it's just hard to find things. That would be incrementally useful. And that is despite the fact that we have a skill set here, starting with, you know, David's experience in building companies through M&A. So there's certainly no reluctance or lack of capability. It's simply just opportunistically, we think we're better off devoting our time, resources, attention to an organic building strategy. But it's always, you know, it's a possibility, and if something comes up that's relevant, we're certainly capable, both with respect to our own human capital as well as our financial capital.

Great. Thank you.

And this does conclude today's conference call. Thank you so much for joining.

You may not disconnect.